Skip to main content
OpenTrials
Completed

NCT Number: NCT05437393

Children's Adaptive Deep Brain Stimulation for Epilepsy Trial (CADET): Pilot

The CADET Pilot will investigate the safety and feasibility of deep brain stimulation (DBS) to treat children with Lennox-Gastaut syndrome using a novel DBS device (Picostim DyNeuMo-1).

Following a 30-day preoperative/baseline assessment phase, all children will have a neurosurgical procedure to implant the device. Implantation will be followed by a 30-day phase of no stimulation (the device is off / inactive) and then a six-month phase of active stimulation (the device is on / active).

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–14 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom

Loading trial locations.

About this study

The CADET pilot will be a single-arm, multi-site, interventional clinical trial. This design has been chosen since this is a feasibility and safety trial in a small number of patients and thus does not primarily aim to determine efficacy.

In this pilot clinical trial, four children with drug-resistant LGS will undergo bilateral CMN DBS.

Following the DBS insertion, all children will undergo one month of inactive ('off') DBS in order to allow the lesioning effect of electrode implantation to dissipate. Thereafter, children will receive active ('on') DBS therapy with standard stimulation parameters for six-months. Following the 'on' phase of the trial, the child will then transition into continuing clinical care and will have their stimulation parameters altered according to clinical evaluation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children enrolled in this study must:

  • Be 5-14 years of age at consent.
  • Have a diagnosis of Lennox-Gastaut Syndrome, as determined by:
  • Slow (<3.0Hz) spike-and-wave pattern and/or fast wave pattern (tonic seizures) on EEG for at least six-months months prior to the enrolment into the baseline period
  • History of drop seizures (tonic, atonic, or tonic-clonic) for at least six-months prior to the enrolment into the baseline period
  • Experience at least 10 seizures per month.
  • Have tried and not responded to two or more antiseizure medications prior to enrolment.
  • Be taking one or more anti-seizure medication(s) at a stable dose for at least the four weeks prior and have a parent/guardian(s) who is willing for their child's maintenance anti-seizure drugs to be unaltered for the trial duration.
  • If on a ketogenic diet, have been established on a stable ketogenic diet for at least 12 weeks prior to screening and the parent/guardian(s) to be willing for child to stay on a stable ketogenic for the duration of the trial.
  • Have a parent/guardian(s) who is willing and able to comply with all the requirements of the study, including the completion of the seizure diary and periodic device charging.

-------------------------------

Exclusion criteria

Children enrolled in this study must not:

  • Have had prior deep brain stimulation insertion.
  • Have an active ('on') vagus nerve stimulator (or active within the six months prior to the baseline period).
  • Have abnormal thalamic anatomy detected on imaging that would render DBS either unsafe or unfeasible.
  • Have a bleeding disorder.
  • Have medical conditions/factors that would increase their anaesthetic risk to an unacceptable level.
  • Have a nickel allergy
  • Be pregnant
  • Participate in contact sports

Treatment and study plan

Deep brain stimulation

Device

Deep brain stimulation of the centromedian nucleus (bilateral)

Primary outcomes

  1. Adverse evens

    Time frame: Following 6-months of active stimulation

    Measured according to pre-determined device-related AEs and SAEs, as well as generic AEs and SAEs.

  2. Willingness of the participants/parents/guardians for the participant to be recruited into the study and to undergo the intervention

    Time frame: Following 6-months of active stimulation

    Consent at baseline

  3. Participant completion of the study

    Time frame: Following 6-months of active stimulation

    Completion of all study activities at study exit

  4. Ability of the participant/parent(s)/guardian(s) to re-charge and maintain the device

    Time frame: Following 6-months of active stimulation

    Device recharging is measured using the Picostim event logs

Secondary outcomes

  1. Relative change in parent-reported seizure frequency

    Time frame: Following 6-months of active stimulation (compared to baseline)

    Measured using parent-reported diaries

  2. Relative change in electrographic-recorded seizure frequency

    Time frame: Following 6-months of active stimulation (compared to baseline)

    Measured using serial electroencephalography (EEG)

  3. Relative change in seizure severity

    Time frame: Following 6-months of active stimulation (compared to baseline)

    Measured using the Hague Seizure Severity Scoring questionnaire. Minimum score = 13; maximum score = 52; with higher seizure severity with ascending values.

  4. Relative change in quality of life

    Time frame: Following 6-months of active stimulation (compared to baseline)

    Measured on the Pediatric Quality of Life Inventory (PedsQL) questionnaire. The minimum score is 0 and the maximum score is 100, with improving quality of life with ascending values.

  5. Relative change in quality of life

    Time frame: Following 6-months of active stimulation (compared to baseline)

    Measured on the Impact of Pediatric Epilepsy Scale (IPES) questionnaires. The minimum score is 0 and the maximum score is 100, with improving quality of life with ascending values.

Other outcomes

  1. Radiological correlates of neurophysiological and clinical response to CMN DBS

    Time frame: Following 6-months of active stimulation

    Analysis of pre-trial MRI brain scan in conjunction with relative change in seizure counts measured using parent-reported diaries

  2. Correlates of the scalp EEG with the intracranial recordings (local field potentials) from the DBS device.

    Time frame: Following 6-months of active stimulation

    Analysis of local-field potentials measured from the DBS device in conjunction with data from the encephalography (EEG) data

Sponsors and collaborators

Lead sponsor

University College, London

Other

Collaborators

  • Great Ormond Street Hospital for Children NHS Foundation Trust
  • King's College Hospital NHS Trust
  • King's College London
  • University of Oxford

Registry information

Acronym: CADET Pilot

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 29, 2022
Registry last updated
Aug 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.